XML 94 R17.htm IDEA: XBRL DOCUMENT
v3.26.1

Discontinued operations | 12 Months Ended
--- | ---
Dec. 31, 2025
Non-Current Assets Held For Sale And Discontinued Operations [Abstract] |
Discontinued operations | Discontinued operations In 2023, the Group discontinued its 2019 novel coronavirus (“COVID-19”) related diagnostic services globally and other DNA testing operations in the EMEA region. This strategic decision was influenced by the World Health Organization's latest pronouncements and the diminishing demand for COVID-19 diagnostic services, primarily attributable to the relaxation of testing mandates for international travelers and local citizens worldwide. Consequently, these developments led to a noticeable decline in the number of testing centers operating in Hong Kong and the United Kingdom for testing samples from the EMEA region. On October 1, 2025, the Group completed the disposal of ACT Genomics. The disposal was part of a strategic shift to streamline operations and exit the clinical diagnostics sector, enabling the Group to focus its resources and capital on the high-growth consumer health market and its core flagship brands. Following the disposal, the Group no longer has exposure to the operations of ACT Genomics. Consequently, the results of ACT Genomics have been classified as discontinued operations in the consolidated financial statements for all periods presented. The results of discontinued operations for the years ended December 31, 2024, 2023, and related disclosures in notes 5, 6, 7, 8 and 9 have also been restated accordingly. Together with the earlier cessation of COVID-19 related diagnostic services and other DNA testing operations in the EMEA region, these actions reflect management’s continued strategic realignment to streamline operations and reallocate resources toward its core businesses in response to evolving market conditions. In accordance with IFRS 5, the above cessation and disposal represent the discontinuation and disposal of components of the Group that constitute separate major lines of business and/or geographical areas of operations, and therefore met the criteria to be classified as discontinued operations as of the respective dates of cessation and disposal. Results of discontinued operations The following is a reconciliation of the amounts of major classes of loss from operations classified as discontinued operations in the consolidated statements of comprehensive loss for the years ended December 31, 2025, 2024, and 2023:
| 2025 |  | 2024 |  | 2023
Revenue | $ | 9,605 |  |  | $ | 14,782 |  |  | $ | 29,050 |
Direct costs | (5,435) |  |  | (8,601) |  |  | (15,288) |
Gross profit | 4,170 |  |  | 6,181 |  |  | 13,762 |
Other income and other net gains | 5,034 |  |  | 785 |  |  | 664 |
Selling and marketing expenses | (2,215) |  |  | (3,223) |  |  | (3,413) |
Research and development expenses | (1,266) |  |  | (1,872) |  |  | (3,679) |
Impairment loss of goodwill | — |  |  | — |  |  | (3,900) |
Administrative and other operating expenses | (10,636) |  |  | (13,722) |  |  | (25,268) |
Loss from operating activities | (4,913) |  |  | (11,851) |  |  | (21,834) |
Share of (loss)/profit of equity-accounted investees, net of tax | (868) |  |  | 231 |  |  | (189) |
Gain on disposal of a subsidiary (note 34) | 2,045 |  |  | — |  |  | — |
Other finance costs | (17) |  |  | (35) |  |  | (196) |
Loss from discontinued operations before taxation | (3,753) |  |  | (11,655) |  |  | (22,219) |
Income tax credit | 22 |  |  | 235 |  |  | 440 |
Loss from discontinued operations, net of tax | $ | (3,731) |  |  | $ | (11,420) |  |  | $ | (21,779) |
Loss per share |  |  |  |  |
Basic | (0.23) |  |  | (0.57) |  |  | (1.79) |
Diluted | (0.23) |  |  | (0.57) |  |  | (1.79) |
During the years ended December 31, 2025, 2024 and 2023, the Diagnostics business within discontinued operations recognized processing service income of approximately $2,312, $2,968, and $1,498, respectively, in respect of processing services provided to the Prevention segment presented within continuing operations (see note 6). In preparing the Group’s consolidated financial statements, the processing service revenue recognized by the Diagnostics business and the corresponding processing service expense recognized by the Prevention segment were eliminated in full on consolidation. As the Diagnostics business is presented within discontinued operations while the Prevention segment remains within continuing operations in the re-presented comparative information, this elimination reduces revenue in discontinued operations and reduces costs in continuing operations. Accordingly, the effect of such intragroup transactions is not reflected on a gross basis within discontinued operations in the re-presented comparative information. Such processing service arrangement is expected to continue after the disposal of the Diagnostics business pursuant to ongoing commercial arrangements. Including the impact of such processing service income, the adjusted loss from discontinued operations, net of tax, would have been approximately $1,419, $8,452 and $20,281, respectively. The loss from discontinued operations attributable to the equity shareholders of the Company amounted to $3,173, $7,086, and $20,155, while loss attributable to non-controlling interests amounted to $558, $4,334, and $1,624 for the years ended December 31, 2025, 2024 and 2023, respectively. The total comprehensive expense from continuing operations of $34,169, $39,045, and $41,493 was attributable entirely to the equity shareholders of the Company for the years ended December 31, 2025, 2024 and 2023, respectively. (a)Revenue Disaggregation of revenue
| 2025 |  | 2024 |  | 2023
External revenue by product line |  |  |  |  |
Prevention and diagnostics - COVID-19 related and EMEA operations | $ | — |  |  | $ | 97 |  |  | $ | 13,462 |
Diagnostics - sale of precision oncology services | 9,605 |  |  | 14,685 |  |  | 15,588 |
| $ | 9,605 |  |  | $ | 14,782 |  |  | $ | 29,050 |
| 2025 |  | 2024 |  | 2023
External revenue by timing of revenue |  |  |  |  |
Goods transferred at a point in time | $ | — |  |  | $ | — |  |  | $ | 1,415 |
Services transferred at a point in time | 9,605 |  |  | 14,782 |  |  | 27,635 |
| $ | 9,605 |  |  | $ | 14,782 |  |  | $ | 29,050 |
Geographical information Information about the Group's revenue from discontinued operations from external customers is presented based on the location of the region of domicile of entities of the Group.
| 2025 |  | 2024 |  | 2023
Hong Kong | $ | 2,394 |  |  | $ | 3,938 |  |  | $ | 15,725 |
United Kingdom | 1,798 |  |  | 2,780 |  |  | 2,816 |
Taiwan | 4,835 |  |  | 7,092 |  |  | 9,325 |
Rest of the world | 578 |  |  | 972 |  |  | 1,184 |
| $ | 9,605 |  |  | $ | 14,782 |  |  | $ | 29,050 |
(b)Other income and other net gains/(losses)
| 2025 |  | 2024 |  | 2023
Bank interest income | $ | 50 |  |  | $ | 193 |  |  | $ | 373 |
Net foreign exchange gains/(losses) | 283 |  |  | 314 |  |  | (71) |
Sundry income | 4,701 |  |  | 278 |  |  | 362 |
| $ | 5,034 |  |  | $ | 785 |  |  | $ | 664 |
(c)Other finance costs
| 2025 |  | 2024 |  | 2023
Interest expenses on lease liabilities | $ | 17 |  |  | $ | 35 |  |  | $ | 196 |
(d)Staff costs
| 2025 |  | 2024 |  | 2023
Salaries, wages and other benefits | $ | 5,647 |  |  | $ | 7,997 |  |  | $ | 17,700 |
Contributions to defined contribution retirement plan | 441 |  |  | 565 |  |  | 597 |
Equity-settled share-based payment expenses | 1,254 |  |  | 2,004 |  |  | 354 |
| $ | 7,342 |  |  | $ | 10,566 |  |  | $ | 18,651 |
Represented by: |  |  |  |  |
Direct costs | $ | 365 |  |  | $ | 492 |  |  | $ | 3,128 |
Selling and marketing expenses | 2,003 |  |  | 2,726 |  |  | 2,536 |
Research and development expenses | 731 |  |  | 1,142 |  |  | 1,598 |
Administrative and other operating expenses | 4,243 |  |  | 6,206 |  |  | 11,389 |
Total staff costs | $ | 7,342 |  |  | $ | 10,566 |  |  | $ | 18,651 |
(e)Other items
| 2025 |  | 2024 |  | 2023
Cost of inventories | $ | 4,449 |  |  | $ | 6,903 |  |  | $ | 8,045 |
Depreciation of |  |  |  |  |
- property, plant and equipment | 407 |  |  | 1,152 |  |  | 1,632 |
- right-of-use assets | 368 |  |  | 840 |  |  | 2,015 |
Amortization of intangible assets | 666 |  |  | 1,457 |  |  | 1,467 |
Write-off on property, plant and equipment | — |  |  | — |  |  | — |
Auditor’s remuneration | 1,162 |  |  | 120 |  |  | 123 |
Freight and delivery charges | 22 |  |  | 59 |  |  | 427 |
Total depreciation and amortization charges represented by: |  |  |  |  |
Direct costs | $ | 226 |  |  | $ | 675 |  |  | $ | 904 |
Research and development expenses | 98 |  |  | 207 |  |  | 611 |
Administrative and other operating expenses | 1,117 |  |  | 2,567 |  |  | 3,599 |
Total depreciation and amortization charges | $ | 1,441 |  |  | $ | 3,449 |  |  | $ | 5,114 |
Cash flows from/(used in) discontinued operations
| 2025 |  | 2024 |  | 2023
Net cash from/(used in) operating activities | $ | 49 |  |  | $ | 5,563 |  |  | $ | (11,420) |
Net cash used in investing activities | (3,539) |  |  | (318) |  |  | (404) |
Net cash used in financing activities | (961) |  |  | (1,413) |  |  | (2,653) |
Net cash (outflows)/inflows for the year | $ | (4,451) |  |  | $ | 3,832 |  |  | $ | (14,477) |
A.COVID-19 diagnostic services and other DNA testing operations in the EMEA region
| 2025 |  | 2024 |  | 2023
Revenue | $ | — |  |  | $ | 97 |  |  | $ | 13,462 |
Direct costs | — |  |  | (39) |  |  | (7,357) |
Gross profit | — |  |  | 58 |  |  | 6,105 |
Other income and other net gains | 4,590 |  |  | 46 |  |  | 290 |
Selling and marketing expenses | — |  |  | (2) |  |  | (632) |
Research and development expenses | — |  |  | — |  |  | (1,189) |
Administrative and other operating expenses | (1,449) |  |  | (82) |  |  | (12,946) |
Profit/(loss) from operating activities | 3,141 |  |  | 20 |  |  | (8,372) |
Other finance costs | — |  |  | — |  |  | (122) |
Profit/(loss) from discontinued operations before taxation | 3,141 |  |  | 20 |  |  | (8,494) |
Income tax credit | — |  |  | — |  |  | 117 |
Profit/(loss) from discontinued operations, net of tax | $ | 3,141 |  |  | $ | 20 |  |  | $ | (8,377) |
Earnings/(losses) per share |  |  |  |  |
Basic | $ | 0.22 |  |  | $ | — |  |  | $ | (0.74) |
Diluted | 0.22 |  |  | — |  |  | (0.74) |
(a)Revenue Disaggregation of revenue
| 2025 |  | 2024 |  | 2023
External revenue by product line |  |  |  |  |
Prevention and diagnostics - COVID-19 related and EMEA operations | $ | — |  |  | $ | 97 |  |  | $ | 13,462 |
| 2025 |  | 2024 |  | 2023
External revenue by timing of revenue |  |  |  |  |
Goods transferred at a point in time | $ | — |  |  | $ | — |  |  | $ | 1,415 |
Services transferred at a point in time | — |  |  | 97 |  |  | 12,047 |
| $ | — |  |  | $ | 97 |  |  | $ | 13,462 |
Geographical information Information about the Group's revenue from discontinued operations from external customers is presented based on the location of the region of domicile of entities of the Group.
| 2025 |  | 2024 |  | 2023
Hong Kong | $ | — |  |  | $ | 97 |  |  | $ | 12,916 |
United Kingdom | — |  |  | — |  |  | 546 |
| $ | — |  |  | $ | 97 |  |  | $ | 13,462 |
(b)Other income and other net gains
| 2025 |  | 2024 |  | 2023
Bank interest income | $ | — |  |  | $ | — |  |  | $ | 19 |
Net foreign exchange (losses)/gains | (4) |  |  | 1 |  |  | (25) |
Sundry income | 4,594 |  |  | 45 |  |  | 296 |
| $ | 4,590 |  |  | $ | 46 |  |  | $ | 290 |
(c)Other finance costs
| 2025 |  | 2024 |  | 2023
Interest expenses on lease liabilities | $ | — |  |  | $ | — |  |  | $ | 122 |
(d)Staff costs
| 2025 |  | 2024 |  | 2023
Salaries, wages and other benefits | $ | — |  |  | $ | — |  |  | $ | 9,122 |
Contributions to defined contribution retirement plan | — |  |  | — |  |  | — |
Equity-settled share-based payment expenses | — |  |  | — |  |  | — |
| $ | — |  |  | $ | — |  |  | $ | 9,122 |
Represented by: |  |  |  |  |
Direct costs | $ | — |  |  | $ | — |  |  | $ | 2,058 |
Selling and marketing expenses | — |  |  | — |  |  | — |
Research and development expenses | — |  |  | — |  |  | — |
Administrative and other operating expenses | — |  |  | — |  |  | 7,064 |
Total staff costs | $ | — |  |  | $ | — |  |  | $ | 9,122 |
(e)Other items
| 2025 |  | 2024 |  | 2023
Cost of inventories | $ | — |  |  | $ | 38 |  |  | $ | 2,761 |
Depreciation of |  |  |  |  |
- property, plant and equipment | — |  |  | — |  |  | 98 |
- right-of-use assets | — |  |  | — |  |  | 1,025 |
Amortization of intangible assets | — |  |  | — |  |  | — |
Write-off on property, plant and equipment | — |  |  | — |  |  | — |
Auditor’s remuneration | — |  |  | — |  |  | 77 |
Freight and delivery charges | — |  |  | — |  |  | 381 |
Total depreciation and amortization charges represented by: |  |  |  |  |
Direct costs | $ | — |  |  | $ | — |  |  | $ | — |
Research and development expenses | — |  |  | — |  |  | 405 |
Administrative and other operating expenses | — |  |  | — |  |  | 718 |
Total depreciation and amortization charges | $ | — |  |  | $ | — |  |  | $ | 1,123 |
Cash flows from/(used in) discontinued operations
| 2025 |  | 2024 |  | 2023
Net cash from/(used in) operating activities | $ | 3,585 |  |  | $ | 80 |  |  | $ | (901) |
Net cash (used in)/from investing activities | (3,301) |  |  | — |  |  | 119 |
Net cash used in financing activities | — |  |  | — |  |  | (1,184) |
Net cash inflows/(outflows) for the year | $ | 284 |  |  | $ | 80 |  |  | $ | (1,966) |
B. ACT Genomics
| 2025 |  | 2024 |  | 2023
Revenue | $ | 9,605 |  |  | $ | 14,685 |  |  | $ | 15,588 |
Direct costs | (5,435) |  |  | (8,562) |  |  | (7,931) |
Gross profit | 4,170 |  |  | 6,123 |  |  | 7,657 |
Other income and other net gains | 444 |  |  | 739 |  |  | 374 |
Selling and marketing expenses | (2,215) |  |  | (3,223) |  |  | (2,781) |
Research and development expenses | (1,266) |  |  | (1,872) |  |  | (2,490) |
Impairment loss of goodwill | — |  |  | — |  |  | (3,900) |
Administrative and other operating expenses | (9,187) |  |  | (13,640) |  |  | (12,322) |
Loss from operating activities | (8,054) |  |  | (11,873) |  |  | (13,462) |
Share of (loss)/profit of equity-accounted investees, net of tax | (868) |  |  | 231 |  |  | (189) |
Gain on disposal of a subsidiary (note 34) | 2,045 |  |  | — |  |  | — |
Other finance costs | (17) |  |  | (35) |  |  | (74) |
Loss from discontinued operations before taxation | (6,894) |  |  | (11,677) |  |  | (13,725) |
Income tax credit | 22 |  |  | 235 |  |  | 323 |
Loss from discontinued operations, net of tax | $ | (6,872) |  |  | $ | (11,442) |  |  | $ | (13,402) |
Loss per share |  |  |  |  |
Basic | (0.45) |  |  | (0.57) |  |  | (1.05) |
Diluted | (0.45) |  |  | (0.57) |  |  | (1.05) |
(a)Revenue Disaggregation of revenue
| 2025 |  | 2024 |  | 2023
External revenue by product line |  |  |  |  |
Diagnostics - sale of precision oncology services | $ | 9,605 |  |  | $ | 14,685 |  |  | $ | 15,588 |
| 2025 |  | 2024 |  | 2023
External revenue by timing of revenue |  |  |  |  |
Services transferred at a point in time | $ | 9,605 |  |  | $ | 14,685 |  |  | $ | 15,588 |
Geographical information Information about the Group's revenue from discontinued operations from external customers is presented based on the location of the region of domicile of entities of the Group.
| 2025 |  | 2024 |  | 2023
Hong Kong | $ | 2,394 |  |  | $ | 3,840 |  |  | $ | 2,809 |
United Kingdom | 1,798 |  |  | 2,780 |  |  | 2,270 |
Taiwan | 4,835 |  |  | 7,092 |  |  | 9,325 |
Rest of the world | 578 |  |  | 973 |  |  | 1,184 |
| $ | 9,605 |  |  | $ | 14,685 |  |  | $ | 15,588 |
(b)Other income and other net gains
| 2025 |  | 2024 |  | 2023
Bank interest income | $ | 50 |  |  | $ | 193 |  |  | $ | 354 |
Net foreign exchange gains/(losses) | 287 |  |  | 313 |  |  | (46) |
Sundry income | 107 |  |  | 233 |  |  | 66 |
| $ | 444 |  |  | $ | 739 |  |  | $ | 374 |
(c)Other finance costs
| 2025 |  | 2024 |  | 2023
Interest expenses on lease liabilities | $ | 17 |  |  | $ | 35 |  |  | $ | 74 |
(d)Staff costs
| 2025 |  | 2024 |  | 2023
Salaries, wages and other benefits | $ | 5,647 |  |  | $ | 7,997 |  |  | $ | 8,578 |
Contributions to defined contribution retirement plan | 441 |  |  | 565 |  |  | 597 |
Equity-settled share-based payment expenses | 1,254 |  |  | 2,004 |  |  | 354 |
| $ | 7,342 |  |  | $ | 10,566 |  |  | $ | 9,529 |
Represented by: |  |  |  |  |
Direct costs | $ | 365 |  |  | $ | 492 |  |  | $ | 1,070 |
Selling and marketing expenses | 2,003 |  |  | 2,726 |  |  | 2,536 |
Research and development expenses | 731 |  |  | 1,142 |  |  | 1,598 |
Administrative and other operating expenses | 4,243 |  |  | 6,206 |  |  | 4,325 |
Total staff costs | $ | 7,342 |  |  | $ | 10,566 |  |  | $ | 9,529 |
(e)Other item s
| 2025 |  | 2024 |  | 2023
Cost of inventories | $ | 4,449 |  |  | $ | 6,866 |  |  | $ | 5,284 |
Depreciation of |  |  |  |  |
- property, plant and equipment | 408 |  |  | 1,152 |  |  | 1,534 |
- right-of-use assets | 367 |  |  | 840 |  |  | 990 |
Amortization of intangible assets | 666 |  |  | 1,457 |  |  | 1,467 |
Write-off on property, plant and equipment | — |  |  | — |  |  | — |
Auditor’s remuneration | 1,162 |  |  | 120 |  |  | 46 |
Freight and delivery charges | 22 |  |  | 59 |  |  | 46 |
Total depreciation and amortization charges represented by: |  |  |  |  |
Direct costs | $ | 226 |  |  | $ | 675 |  |  | $ | 904 |
Research and development expenses | 98 |  |  | 207 |  |  | 206 |
Administrative and other operating expenses | 1,117 |  |  | 2,567 |  |  | 2,881 |
Total depreciation and amortization charges | $ | 1,441 |  |  | $ | 3,449 |  |  | $ | 3,991 |
Cash flows (used in)/from discontinued operations
| 2025 |  | 2024 |  | 2023
Net cash (used in)/from operating activities | $ | (3,536) |  |  | $ | 5,483 |  |  | $ | (10,519) |
Net cash used in investing activities | (238) |  |  | (318) |  |  | (523) |
Net cash used in financing activities | (961) |  |  | (1,413) |  |  | (1,469) |
Net cash (outflows)/inflows for the year | $ | (4,735) |  |  | $ | 3,752 |  |  | $ | (12,511) |

X
- Definition The disclosure of discontinued operations. [Refer: Discontinued operations [member]] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Note Expiry date 2027-01-01 -Name IAS -Number 1 -IssueDate 2025-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non-Current Assets Held For Sale And Discontinued Operations + References No definition available. + Details
Name: | pre_NonCurrentAssetsHeldForSaleAndDiscontinuedOperationsAbstract
Namespace Prefix: | pre_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration